InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
InflaRx announced a strategic advancement of its oral C5aR inhibitor izicopan into ANCA-associated vasculitis (AAV), with Phase 2 planning underway and an eye toward an expedited regulatory path. The company also intends to establish rapid proof of concept in other renal diseases including aHUS, IgAN, and C3G, with open-label studies expected to generate data next year.
Key figures
- Drug Name
- izicopan
- Phase Of Trial
- Phase 2
- Cash runway
- through 2029
- C5a blockade
- ≥90%
- Market potential hs
- $1.5 billion per year
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.